Top

Endocrine

Published in:

26-12-2023 | Original Article

Intestinal Trefoil Factor 3: a new biological factor mediating gut-kidney crosstalk in diabetic kidney disease

Authors: Tao Zhang, Yinghui Zhang, Jie Tao, Xianglu Rong, Yiqi Yang

Published in: Endocrine | Issue 1/2024

Abstract

Purpose

To investigate the effect of TFF3 in the pathogenesis of Diabetic Kidney Disease (DKD), and explore the dynamic changes of TFF3 expression pattern in renal injury process.

Methods

DKD animal model was established by streptozotocin (STZ) (40 mg/kg/d, ip, for 5 days, consecutively) combined with the high fat diet (HFD) for 12 weeks. While animals were sacrificed at different time stages in DKD process (4 weeks, 8 weeks and 12 weeks, respectively).

Results

STZ combined with high-fat diet induced weight gain, increased blood glucose and decreased glucose tolerance in DKD mice. Compared to the control group, the DKD group exhibits extracellular matrix (ECM) accumulation and the renal injury was aggravated in a time-dependent manner. The TFF3 expression level was decreased in kidney, and increased in colon tissue.

Conclusion

TFF3 is not only expressed in colon, but also expressed in renal medulla and cortex. TFF3 might be play a pivotal role in renal mucosal repair by gut-kidney crosstalk, and protect renal from high glucose microenvironment damage.

H. Sun, P. Saeedi, S. Karuranga et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pr. 183, 109–119 (2022). https://doi.org/10.1016/j.diabres.2021.109119CrossRef

C. Lin, Y. Hsu, Y. Huang, Y. Shih, C. Wang, W. Chiang, P. Chang, A KDM6A-KLF10 reinforcing feedback mechanism aggravates diabetic podocyte dysfunction. EMBO Mol. Med. 11(5), (2019). https://doi.org/10.15252/emmm.201809828

C.J. May, G.I. Welsh, M. Chesor, P.J. Lait, L.P. Schewitz-Bowers, R.W.J. Lee, M.A. Saleem, Human Th17 cells produce a soluble mediator that increases podocyte motility via signaling pathways that mimic PAR-1 activation. Am. J. Physiol. Ren. Physiol. 317(4), F913–F921 (2019). https://doi.org/10.1152/ajprenal.00093.2019CrossRef

Y. Li, Y. Lu, D. Tang et al. Anthocyanin improves kidney function in diabetic kidney disease by regulating amino acid metabolism. J. Transl. Med. 20(1), 510 (2022). https://doi.org/10.1186/s12967-022-03717-9CrossRefPubMedPubMedCentral

Y. Yang, Z. Lin, Q. Lin, W. Bei, J. Guo, Pathological and therapeutic roles of bioactive peptide trefoil factor 3 in diverse diseases: recent progress and perspective. Cell Death Dis. 13(1), 62 (2022). https://doi.org/10.1038/s41419-022-04504-6CrossRefPubMedPubMedCentral

L. Thim, F. May, Structure of mammalian trefoil factors and functional insights. Cell Mol. Life Sci. 62(24), 2956–2973 (2005). https://doi.org/10.1007/s00018-005-5484-6CrossRefPubMed

X. Wu, H. Zheng, R. Yang et al. Mouse trefoil factor 3 ameliorated high-fat-diet-induced hepatic steatosis via increasing peroxisome proliferator-activated receptor-alpha-mediated fatty acid oxidation. Am. J. Physiol. Endocrinol. Metab. 317(3), E436–E445 (2019). https://doi.org/10.1152/ajpendo.00454.2018CrossRefPubMed

J. Zou, Z. Chen, C. Liang et al. Trefoil Factor 3, cholinesterase and homocysteine: potential predictors for parkinson’s disease dementia and vascular parkinsonism dementia in advanced stage. Aging Dis. 9(1), 51–65 (2018). https://doi.org/10.14336/AD.2017.0416CrossRefPubMedPubMedCentral

D. Taupin, J. Pedersen, M. Familari, G. Cook, N. Yeomans, A.S. Giraud, Augmented intestinal trefoil factor (TFF3) and loss of pS2 (TFF1) expression precedes metaplastic differentiation of gastric epithelium. Lab. Investig. 81(3), 397–408 (2001). https://doi.org/10.1038/labinvest.3780247CrossRefPubMed

10.

N.M. Belle, Y. Ji, K. Herbine et al. TFF3 interacts with LINGO2 to regulate EGFR activation for protection against colitis and gastrointestinal helminths. Nat. Commun. 10(1), 4408 (2019). https://doi.org/10.1038/s41467-019-12315-1CrossRefPubMedPubMedCentral

11.

H. Cui, S. Wang, F. Song et al. CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression. Signal Transduct. Target Ther. 6(1), 268 (2021). https://doi.org/10.1038/s41392-021-00677-2CrossRefPubMedPubMedCentral

12.

T. Du, H. Luo, H. Qin, F. Wang, Q. Wang, Y. Xiang, Y. Zhang, Circulating Serum Trefoil Factor 3 (TFF3) is dramatically increased in chronic kidney disease. PLoS One 8(11), e80271 (2013). https://doi.org/10.1371/journal.pone.0080271CrossRefPubMedPubMedCentral

13.

B.R. Griffin, S. Faubel, C.L. Edelstein, Biomarkers of drug-induced kidney toxicity. Ther. Drug Monit. 41(2), 213–226 (2019). https://doi.org/10.1097/FTD.0000000000000589CrossRefPubMedPubMedCentral

14.

M.E. Grams, A. Surapaneni, J. Chen et al. Proteins associated with risk of kidney function decline in the general population. J. Am. Soc. Nephrol. 32(9), 2291–2302 (2021). https://doi.org/10.1681/ASN.2020111607CrossRefPubMedPubMedCentral

15.

S. Anand, M. Bajpai, T. Khanna, A. Kumar, Influence of genetic polymorphism in renin-angiotensin system-candidate genes on urinary trefoil family factor 3 levels in children with congenital anomalies of kidney and urinary tract. Pediatr. Nephrol. 37(1), 139–145 (2022). https://doi.org/10.1007/s00467-021-05160-2CrossRefPubMed

16.

S. Anand, M. Bajpai, T. Khanna, A. Kumar, Urinary biomarkers as point-of-care tests for predicting progressive deterioration of kidney function in congenital anomalies of kidney and urinary tract: trefoil family factors (TFFs) as the emerging biomarkers. Pediatr. Nephrol. 36(6), 1465–1472 (2021). https://doi.org/10.1007/s00467-020-04841-8CrossRefPubMed

17.

Y. Yang, H. Tan, X. Zhang et al. The Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against renal injury and inflammation in mice with diabetic kidney disease. J. Ethnopharmacol. 292, 115–165 (2022). https://doi.org/10.1016/j.jep.2022.115165CrossRef

18.

P.M. Titchenell, Q. Chu, B.R. Monks, M.J. Birnbaum, Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo. Nat. Commun. 6, 70–78 (2015). https://doi.org/10.1038/ncomms8078CrossRef

19.

L. Xu, X. Li, F. Zhang, L. Wu, Z. Dong, D. Zhang, EGFR drives the progression of AKI to CKD through HIPK2 overexpression. Theranostics 9(9), 2712–2726 (2019). https://doi.org/10.7150/thno.31424CrossRefPubMedPubMedCentral

20.

S. Li, J. Park, Y. Guan, K. Chung, R. Shrestha, M.B. Palmer, K. Susztak, DNMT1 in Six2 progenitor cells is essential for transposable element silencing and kidney development. J. Am. Soc. Nephrol. 30(4), 594–609 (2019). https://doi.org/10.1681/ASN.2018070687CrossRefPubMedPubMedCentral

21.

L. Marko, E. Vigolo, C. Hinze et al. Tubular Epithelial NF-kappa B activity regulates Ischemic AKI. J. Am. Soc. Nephrol. 27(9), 2658–2669 (2016). https://doi.org/10.1681/ASN.2015070748CrossRefPubMedPubMedCentral

22.

J. Ren, L. Han, J. Tang et al. Foxp1 is critical for the maintenance of regulatory T-cell homeostasis and suppressive function. PLoS Biol. 17(5), e3000270 (2019). https://doi.org/10.1371/journal.pbio.3000270CrossRefPubMedPubMedCentral

23.

Y. Liu, K. Wang, X. Liang et al. Complement C3 produced by macrophages promotes renal fibrosis via IL-17A secretion. Front. Immunol. 9, 02385 (2018). https://doi.org/10.3389/fimmu.2018.02385CrossRef

24.

L. Liu, T. Tao, S. Liu et al. An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness. Nat. Commun. 12(1), 2693 (2021). https://doi.org/10.1038/s41467-021-22971-xCrossRefPubMedPubMedCentral

25.

U. Erben, C. Loddenkemper, K. Doerfel et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J. Clin. Exp. Pathol. 7(8), 4557–4576 (2014)PubMedPubMedCentral

26.

T. Yamanari, H. Sugiyama, K. Tanaka et al. Urine trefoil factors as prognostic biomarkers in chronic kidney disease. Biomed. Res. Int. 2018, 3024698 (2018). https://doi.org/10.1155/2018/3024698CrossRefPubMedPubMedCentral

27.

K. Tanaka, H. Sugiyama, T. Yamanari et al. Renal expression of trefoil factor 3 mRNA in association with tubulointerstitial fibrosis in IgA nephropathy. Nephrology 23(9), 855–862 (2018). https://doi.org/10.1111/nep.13444CrossRefPubMed

28.

S. Khummuang, W. Phanphrom, W. Laopajon, W. Kasinrerk, P .Chaiyarit, S. Pata, Production of monoclonal antibodies against human trefoil factor 3 and development of a modified-sandwich ELISA for detection of trefoil factor 3 homodimer in saliva. Biol. Proced. Online. 19(14), (2017). https://doi.org/10.1186/s12575-017-0064-3

29.

Y. Wang, Y. Liang, W. Zhao, G. Fu, Q. Li, X. Min, Y. Guo, Circulating miRNA-21 as a diagnostic biomarker in elderly patients with type 2 cardiorenal syndrome. Sci. Rep. 10(1), 4894 (2020). https://doi.org/10.1038/s41598-020-61836-zCrossRefPubMedPubMedCentral

30.

R. Jahan, A. Shah, S.G. Kisling, M.A. Macha, S. Thayer, S.K. Batra, S. Kaur, Odyssey of trefoil factors in cancer: diagnostic and therapeutic implications. Biochim. Biophys. Acta Rev. Cancer 1873(2), 188362 (2020). https://doi.org/10.1016/j.bbcan.2020.188362CrossRefPubMed

31.

F.E.B. May, B.R. Westley, TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer. Endocr. Relat. Cancer 22(3), 465–479 (2015). https://doi.org/10.1530/ERC-15-0129CrossRefPubMedPubMedCentral

32.

Y. Yu, H. Jin, D. Holder et al. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat. Biotechnol. 28(5), 470–477 (2010). https://doi.org/10.1038/nbt.1624CrossRefPubMed

33.

Y. Xue, L. Shen, Y. Cui et al. Tff3, as a novel peptide, regulates hepatic glucose metabolism. PloS One 8(9), e75240 (2013). https://doi.org/10.1371/journal.pone.0075240CrossRefPubMedPubMedCentral

34.

K. Krueger, S. Schmid, F. Paulsen et al. Trefoil Factor 3 (TFF3) is involved in cell migration for skeletal repair. Int J. Mol. Sci. 20(17), 4277 (2019). https://doi.org/10.3390/ijms20174277CrossRef

35.

B.C. Astor, A. Koettgen, S. Hwang, N.A. Bhavsar, C.S. Fox, J. Coresh, Trefoil Factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study. Am. J. Nephrol. 34(4), 291–297 (2011). https://doi.org/10.1159/000330699CrossRefPubMedPubMedCentral

36.

J. Guo, M. Sun, X. Teng, L. Xu, MicroRNA-7-5p regulates the expression of TFF3 in inflammatory bowel disease. Mol. Med. Rep. 16(2), 1200–1206 (2017). https://doi.org/10.3892/mmr.2017.6730CrossRefPubMedPubMedCentral

37.

J. Liu, S.Y. Kim, S. Shin et al. Overexpression of TFF3 is involved in prostate carcinogenesis via blocking mitochondria-mediated apoptosis. Exp. Mol. Med 50(8), 1–11 (2018). https://doi.org/10.1038/s12276-018-0137-7CrossRefPubMedPubMedCentral

38.

Y. Zhu, S. Zhao, Y. Deng et al. Hepatic GALE regulates whole-body glucose homeostasis by modulating Tff3 expression. Diabetes 66(11), 2789–2799 (2017). https://doi.org/10.2337/db17-0323CrossRefPubMedPubMedCentral

Title: Intestinal Trefoil Factor 3: a new biological factor mediating gut-kidney crosstalk in diabetic kidney disease
Authors: Tao Zhang
Yinghui Zhang
Jie Tao
Xianglu Rong
Yiqi Yang
Publication date: 26-12-2023
Publisher: Springer US
Published in: Endocrine / Issue 1/2024
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-023-03559-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Lost in translation: evaluating the readability of online patient information for neuroendocrine tumors

Fibrinogen/albumin ratio and carotid artery plaques in coronary heart disease patients with different glucose metabolic states: a RCSCD-TCM study

Effects of eight-week regular high-intensity interval training and hemp (Cannabis sativa L.) seed on total testosterone level among sedentary young males: double-blind, randomized, controlled clinical trial

Serum sex hormones correlate with pathological features of papillary thyroid cancer

Auxological and metabolic effects of long-term treatment with recombinant growth hormone in children born small for gestational age: a retrospective study

Association of serum osteocalcin with bone microarchitecture and muscle mass in Beijing community-dwelling postmenopausal women

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials